Cretostimogene grenadenorepvec
CG Oncology, Inc. CGON · Non Muscle Invasive Bladder Cancer; Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer; Urologic Cancer; Urothelial Carcinoma
Key figures
Next catalyst
None scheduled
Only dates with a source are listed
Phase
Phase 3
Not recorded
Linked trials
2
From ClinicalTrials.gov
Latest FDA action
None on record
From Drugs@FDA
Recalls, shortages, patents and EU status at a glance
Key information
- Sponsor
- CG Oncology, Inc. CGON Source: Company record for CG Oncology, Inc. (opens in a new tab)
- Indications
- Non Muscle Invasive Bladder Cancer; Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer; Urologic Cancer; Urothelial Carcinoma Source: Conditions from ClinicalTrials.gov (opens in a new tab)
- Designations
- None recorded
- Next catalyst
- None scheduled
Development timeline
- Preclinical Completed
- Phase 1 Completed
- Phase 2 Completed
- Phase 3 Current stageFirst trial start 27 Oct 20202 linked trials
- Filed Not yet
- Approved Not yet
Overview
- Mechanism
- Not recorded
- Route
- Not recorded
- Modality
- Not recorded
- Specialties
- Not recorded
Overview text is written by HealthTrade editors.
Key dates
No catalysts yet. Editors add each date together with its source.
FDA designations
No FDA designations are on record for Cretostimogene grenadenorepvec. Editors add each one with its source.
Filed application
No filed application is on record for Cretostimogene grenadenorepvec. Approvals are listed under FDA actions.
FDA advisory committees
No FDA advisory committee meetings are on record for Cretostimogene grenadenorepvec.
Clinical trials
| Trial | Title | Phase | Status | Enrollment | Primary completion | Results posted |
|---|---|---|---|---|---|---|
| NCT06111235ClinicalTrials.gov record for NCT06111235 (opens in a new tab) | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Phase 3 | Active, not recruiting | 367 (actual) | Nov 2026 (estimated) | No |
| NCT04452591ClinicalTrials.gov record for NCT04452591 (opens in a new tab)BOND-003 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Phase 3 | Active, not recruiting | 190 (estimated) | 16 Jun 2030 (estimated) | No |
Publications listing BOND-003 (1), newest first
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies. | ||||||
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Posted results are shown as ClinicalTrials.gov prints them; results from company and journal sources are entered by editors and listed separately. Full result tables are on ClinicalTrials.gov.
Trial quality
About CT-VCALoading trial quality…
FDA actions
No FDA approvals on record for this drug.
FDA recalls load here.
FDA drug shortages load here.
Orange Book patents load here.
FAERS adverse event counts load here.
Papers and preprints load here.
Community discussion loads here.
EU status (EMA)
EMA's medicines data lists no human medicine with the same active substance as Cretostimogene grenadenorepvec.
Source: European Medicines Agency (EMA), medicines data download.
Related news
No recent headlines mention this drug.
Sources
- ClinicalTrials.gov NCT04452591 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
- ClinicalTrials.gov NCT06111235 (opens in a new tab) Licence: public-domain. Official registry record this listing came from
Record updated .
Get the Daily Pulse
PDUFA dates, FDA decisions and the day's health news in one email, each item linked to its source.
Dates come from company and FDA disclosures and can change. Nothing on this page is investment advice.